Amgen Inc (AMGN)

152.93
3.60 2.30
NASDAQ : Health Care
Prev Close 156.51
Open 153.59
Day Low/High 152.66 / 154.60
52 Wk Low/High 130.09 / 181.81
Volume 3.76M
Avg Volume 3.60M
Exchange NASDAQ
Shares Outstanding 735.40M
Market Cap 116.16B
EPS 10.30
P/E Ratio 15.00
Div & Yield 4.60 (2.90%)

Latest News

Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating

Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating

Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating

UCB Stock Plunges After Trials Reveal Safety Risk in Amgen JV

UCB Stock Plunges After Trials Reveal Safety Risk in Amgen JV

UCB stock plummeted Monday after clinical trials shone a light over a possible safety risk related to the Osteoporosis treatment that it has been developing alongside Amgen

Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis

Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis

ARCH Study Met Primary and Key Secondary Endpoints by Reducing the Incidence of New Vertebral, Clinical and Non-Vertebral Fractures

Repatha® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets

Repatha® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets

New Analysis From Cardiovascular Outcomes Trial Shows Addition of Repatha in Patients Considered at Goal Further Reduces Cardiovascular Event Risk

Amgen Submits Biologics License Application To The FDA For Erenumab

Amgen Submits Biologics License Application To The FDA For Erenumab

Erenumab is an Investigative Treatment Specifically Designed to Prevent Migraine

Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio

Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio

Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic Acid in Treatment of Myeloma Bone Disease

Here Are Some of Congress' Favorite Stocks

Here Are Some of Congress' Favorite Stocks

While hard at work in Washington, a handful of members of Congress have also been busy trading stocks.

STMicroelectronics, Chipotle, Simpson Manufacturing: 'Mad Money' Lightning Round

STMicroelectronics, Chipotle, Simpson Manufacturing: 'Mad Money' Lightning Round

Jim Cramer is bullish on STMicroelectronics, Chipotle Mexican Grill, Simpson Manufacturing.

Trump Resurrects Talk of 10% Tax Holiday in Big Gift to Tech

Trump Resurrects Talk of 10% Tax Holiday in Big Gift to Tech

President Trump delivered some good news to tech giants and other corporations hoarding loads of cash abroad -- a 10% repatriation holiday is back on the table.

Dollar Is Being Ignored

But if it keeps progressing, that could change a few things.

Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha® (Evolocumab)

Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha® (Evolocumab)

Harvard Pilgrim Refines the Utilization Management Criteria to Help High-Risk Cardiovascular Patients Access Repatha

Amgen, Brooks Automation, Alaska Air: 'Mad Money' Lightning Round May 1

Amgen, Brooks Automation, Alaska Air: 'Mad Money' Lightning Round May 1

Amgen is controversial, while Alaska Air and Southwest remain two of Cramer's favorites.

Apple, Facebook, Netflix Flying High: Cramer's 'Mad Money' Recap (Monday 5/1/17)

Apple, Facebook, Netflix Flying High: Cramer's 'Mad Money' Recap (Monday 5/1/17)

With earnings due this week from Apple and Facebook, the so-called FAANG stocks are flying high.

Merger Buzz Drives Akorn to Top of Health Chart in April

Merger Buzz Drives Akorn to Top of Health Chart in April

Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.

PayPal Propels Nasdaq to New Record; Dow and S&P 500 Post Small Gains

PayPal Propels Nasdaq to New Record; Dow and S&P 500 Post Small Gains

Better-than-expected earnings from PayPal drove the Nasdaq to new records, while a slump in crude oil kneecaps any big gains for the rest of the market.

Closing Bell: PayPal Pushes Nasdaq to New Record; Crude Ends at One-Month Low

Closing Bell: PayPal Pushes Nasdaq to New Record; Crude Ends at One-Month Low

Better-than-expected earnings from PayPal drove the Nasdaq to new records, while a slump in crude oil kneecaps any big gains for the rest of the market.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

Stocks hold onto slight to modest gains Thursday afternoon after positive earnings help to offset a slump in crude oil prices and a decline in energy names.

Stocks Turn Mixed in Face of Crude Oil Slump

Stocks Turn Mixed in Face of Crude Oil Slump

Stocks turn mixed on Thursday after a slump in crude oil prices, and a decline in energy names, snarl earlier upward momentum.

Stock Futures Higher as Positive Earnings Offset Weaker Durable Goods Orders

Stock Futures Higher as Positive Earnings Offset Weaker Durable Goods Orders

Stock futures creep higher on Thursday as Wall Street returns its attention to positive earnings for market direction after a day focused on the White House's tax reform plans.

Amgen Reports Mixed Financials Results as Its Lead Drug, Enbrel, Sees Sales Decrease

Amgen Reports Mixed Financials Results as Its Lead Drug, Enbrel, Sees Sales Decrease

The drug company maintained its 2017 guidance, but sales of two of its key drugs registered disappointing results, and shares were down in after-hours trading 3%.

Market Recon: Today Is the Day You've Been Waiting For

Market Recon: Today Is the Day You've Been Waiting For

It is the day when the White House launches the start of President Trump's tax reform.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures are rising Wednesday as Wall Street awaits an announcement on tax cuts from the Trump administration.

Cramer: Nasdaq 6000 (the Number) vs. Nasdaq 2000 (the Year)

Cramer: Nasdaq 6000 (the Number) vs. Nasdaq 2000 (the Year)

You think the exchange is overvalued? I don't, and here's why.

Novartis, Amgen Divvy Global Marketing of New Migraine Drug

Novartis, Amgen Divvy Global Marketing of New Migraine Drug

Estimates for erenumab annual sales run as high as $2.3 billion.